Ward Hadaway chosen as UK legal advisor by life science specialist Clinical Laserthermia Systems
16th July 2015
Sweden-based life sciences company, Clinical Laserthermia Systems, carrying out pioneering work in the field of cancer treatment, has appointed Ward Hadaway as its UK legal advisor.
Clinical Laserthermia Systems (CLS), which is a publicly traded company headquartered in Sweden, has chosen Ward Hadaway as its UK legal counsel on the back of the law firm’s strong reputation in the life sciences sector.
CLS develops and markets heat-induced cancer immunotherapy for gentle and effective treatment of most types of solid cancer tumors. Its technology and treatment is based on more than 20 years of research which has resulted in a CE-marked and 510(k) approved medical device.
The method is designed to achieve local tumor destruction and specific antitumor immune response. The laser-generated heat induces destruction of the targeted tumor.
The treatment process is controlled by tissue temperature feedback, which gives close control of temperature levels, which is critical in order to activate the immune system.
The company is now carrying out a clinical study program in Europe and is preparing for possible activities in the UK.
Melanie Yeomans, Corporate Partner at Ward Hadaway, said: “We are delighted that CLS has chosen Ward Hadaway as its legal advisor in the UK.
“The company is involved in ground-breaking work in a vital part of the life sciences sector and its technology has the potential to tackle a wide range of cancers.
“We are looking forward to working with the team at CLS as they continue to develop treatments which could help millions of people across the world.”
Hans von Celsing, chairman of CLS, said: “We are impressed by Ward Hadaway’s experience in our field of business and very pleased by having the firm as CLS’ legal advisor in the UK.”